Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High Risk Pancreatic Neuroendocrine Tumors

Sponsor:

SWOG

Sponsor Study ID:

S2104

CTO #:

103588

NCT Number:

NCT05040360

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Pancreas

Study Objectives:

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)